Back to Peptides
Weight Loss
CagriSema
CagriSema is an investigational fixed-dose combination pairing the amylin analog cagrilintide with the GLP-1 agonist semaglutide. The rationale under study is that dual appetite-regulating pathways may produce greater satiety and weight reduction than either agent alone.
Weight LossMetabolicAmylin/GLP-1SC
Research Benefits
Dual amylin + GLP-1 satiety mechanism studied
Enhanced weight reduction under investigation
Once-weekly dosing profile
Metabolic outcomes in phase 3 evaluation
Axo's Research Digest
An AI-generated, plain-English overview of what the research explores for CagriSema — and how mature that evidence is.